Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?

Detalhes bibliográficos
Autor(a) principal: Viana,Publio Cesar Cavalcanti
Data de Publicação: 2019
Outros Autores: Horvat,Natally, Santos Júnior,Valter Ribeiro dos, Lima,Thais Carneiro, Romão,Davi dos Santos, Cerri,Luciana Mendes de Oliveira, Castro,Marilia Germanos de, Vargas,Herbert Alberto, Miranda,Júlia Azevedo, Leite,Claudia da Costa, Cerri,Giovanni Guido
Tipo de documento: Artigo
Idioma: eng
Título da fonte: International Braz J Urol (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724
Resumo: ABSTRACT Objectives To evaluate the diagnostic performance and interobserver agreement of PI-RADS v2. Materials and Methods In this Institutional Review Board approved single-center retrospective study, 98 patients with clinically suspected PCa who underwent 3-T multiparametric MRI followed by MRI/TRUS fusion-guided prostate biopsy were included from June 2013 to February 2015. Two radiologists (R1 and R2) with 8 and 1 years of experience in abdominal radiology reviewed the MRI scans and assigned PI-RADS v2 scores in all prostate zones. PI-RADS v2 were compared to MRI/TRUS fusion-guided biopsy results, which were classified as negative, PCa, and significant PCa (sPCa). Results Sensitivity, specificity, NPV, PPV and accuracy for PCa was 85.7% (same for all metrics) for R1 and 81.6%, 79.6%, 81.2%, 80.0% and 80.6% for R2. For detecting sPCa, the corresponding values were 95.3%, 85.4%, 95.9%, 83.7% and 89.8% for R1 and 93.0%, 81.8%, 93.7%, 86.7% and 86.7% for R2. There was substantial interobserver agreement in assigning PI-RADS v2 score as negative (1, 2, 3) or positive (4, 5) (Kappa=0.78). On multivariate analysis, PI-RADS v2 (p <0.001) was the only independent predictor of sPCa compared with age, abnormal DRE, prostate volume, PSA and PSA density. Conclusions Our study population demonstrated that PI-RADS v2 had high diagnostic accuracy, substantial interobserver agreement, and it was the only independent predictor of sPCa.
id SBU-1_f6ac6be90a82a6ae95b676f987b1cc91
oai_identifier_str oai:scielo:S1677-55382019000400724
network_acronym_str SBU-1
network_name_str International Braz J Urol (Online)
repository_id_str
spelling Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?ProstateMagnetic Resonance ImagingNeoplasmsProstatic NeoplasmsABSTRACT Objectives To evaluate the diagnostic performance and interobserver agreement of PI-RADS v2. Materials and Methods In this Institutional Review Board approved single-center retrospective study, 98 patients with clinically suspected PCa who underwent 3-T multiparametric MRI followed by MRI/TRUS fusion-guided prostate biopsy were included from June 2013 to February 2015. Two radiologists (R1 and R2) with 8 and 1 years of experience in abdominal radiology reviewed the MRI scans and assigned PI-RADS v2 scores in all prostate zones. PI-RADS v2 were compared to MRI/TRUS fusion-guided biopsy results, which were classified as negative, PCa, and significant PCa (sPCa). Results Sensitivity, specificity, NPV, PPV and accuracy for PCa was 85.7% (same for all metrics) for R1 and 81.6%, 79.6%, 81.2%, 80.0% and 80.6% for R2. For detecting sPCa, the corresponding values were 95.3%, 85.4%, 95.9%, 83.7% and 89.8% for R1 and 93.0%, 81.8%, 93.7%, 86.7% and 86.7% for R2. There was substantial interobserver agreement in assigning PI-RADS v2 score as negative (1, 2, 3) or positive (4, 5) (Kappa=0.78). On multivariate analysis, PI-RADS v2 (p <0.001) was the only independent predictor of sPCa compared with age, abnormal DRE, prostate volume, PSA and PSA density. Conclusions Our study population demonstrated that PI-RADS v2 had high diagnostic accuracy, substantial interobserver agreement, and it was the only independent predictor of sPCa.Sociedade Brasileira de Urologia2019-08-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724International braz j urol v.45 n.4 2019reponame:International Braz J Urol (Online)instname:Sociedade Brasileira de Urologia (SBU)instacron:SBU10.1590/s1677-5538.ibju.2018.0382info:eu-repo/semantics/openAccessViana,Publio Cesar CavalcantiHorvat,NatallySantos Júnior,Valter Ribeiro dosLima,Thais CarneiroRomão,Davi dos SantosCerri,Luciana Mendes de OliveiraCastro,Marilia Germanos deVargas,Herbert AlbertoMiranda,Júlia AzevedoLeite,Claudia da CostaCerri,Giovanni Guidoeng2019-08-30T00:00:00Zoai:scielo:S1677-55382019000400724Revistahttp://www.brazjurol.com.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||brazjurol@brazjurol.com.br1677-61191677-5538opendoar:2019-08-30T00:00International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)false
dc.title.none.fl_str_mv Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
title Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
spellingShingle Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
Viana,Publio Cesar Cavalcanti
Prostate
Magnetic Resonance Imaging
Neoplasms
Prostatic Neoplasms
title_short Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
title_full Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
title_fullStr Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
title_full_unstemmed Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
title_sort Is possible to rule out clinically significant prostate cancer using PI-RADS v2 for the assessment of prostate MRI?
author Viana,Publio Cesar Cavalcanti
author_facet Viana,Publio Cesar Cavalcanti
Horvat,Natally
Santos Júnior,Valter Ribeiro dos
Lima,Thais Carneiro
Romão,Davi dos Santos
Cerri,Luciana Mendes de Oliveira
Castro,Marilia Germanos de
Vargas,Herbert Alberto
Miranda,Júlia Azevedo
Leite,Claudia da Costa
Cerri,Giovanni Guido
author_role author
author2 Horvat,Natally
Santos Júnior,Valter Ribeiro dos
Lima,Thais Carneiro
Romão,Davi dos Santos
Cerri,Luciana Mendes de Oliveira
Castro,Marilia Germanos de
Vargas,Herbert Alberto
Miranda,Júlia Azevedo
Leite,Claudia da Costa
Cerri,Giovanni Guido
author2_role author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Viana,Publio Cesar Cavalcanti
Horvat,Natally
Santos Júnior,Valter Ribeiro dos
Lima,Thais Carneiro
Romão,Davi dos Santos
Cerri,Luciana Mendes de Oliveira
Castro,Marilia Germanos de
Vargas,Herbert Alberto
Miranda,Júlia Azevedo
Leite,Claudia da Costa
Cerri,Giovanni Guido
dc.subject.por.fl_str_mv Prostate
Magnetic Resonance Imaging
Neoplasms
Prostatic Neoplasms
topic Prostate
Magnetic Resonance Imaging
Neoplasms
Prostatic Neoplasms
description ABSTRACT Objectives To evaluate the diagnostic performance and interobserver agreement of PI-RADS v2. Materials and Methods In this Institutional Review Board approved single-center retrospective study, 98 patients with clinically suspected PCa who underwent 3-T multiparametric MRI followed by MRI/TRUS fusion-guided prostate biopsy were included from June 2013 to February 2015. Two radiologists (R1 and R2) with 8 and 1 years of experience in abdominal radiology reviewed the MRI scans and assigned PI-RADS v2 scores in all prostate zones. PI-RADS v2 were compared to MRI/TRUS fusion-guided biopsy results, which were classified as negative, PCa, and significant PCa (sPCa). Results Sensitivity, specificity, NPV, PPV and accuracy for PCa was 85.7% (same for all metrics) for R1 and 81.6%, 79.6%, 81.2%, 80.0% and 80.6% for R2. For detecting sPCa, the corresponding values were 95.3%, 85.4%, 95.9%, 83.7% and 89.8% for R1 and 93.0%, 81.8%, 93.7%, 86.7% and 86.7% for R2. There was substantial interobserver agreement in assigning PI-RADS v2 score as negative (1, 2, 3) or positive (4, 5) (Kappa=0.78). On multivariate analysis, PI-RADS v2 (p <0.001) was the only independent predictor of sPCa compared with age, abnormal DRE, prostate volume, PSA and PSA density. Conclusions Our study population demonstrated that PI-RADS v2 had high diagnostic accuracy, substantial interobserver agreement, and it was the only independent predictor of sPCa.
publishDate 2019
dc.date.none.fl_str_mv 2019-08-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382019000400724
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1677-5538.ibju.2018.0382
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Urologia
publisher.none.fl_str_mv Sociedade Brasileira de Urologia
dc.source.none.fl_str_mv International braz j urol v.45 n.4 2019
reponame:International Braz J Urol (Online)
instname:Sociedade Brasileira de Urologia (SBU)
instacron:SBU
instname_str Sociedade Brasileira de Urologia (SBU)
instacron_str SBU
institution SBU
reponame_str International Braz J Urol (Online)
collection International Braz J Urol (Online)
repository.name.fl_str_mv International Braz J Urol (Online) - Sociedade Brasileira de Urologia (SBU)
repository.mail.fl_str_mv ||brazjurol@brazjurol.com.br
_version_ 1750318076865282048